Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands zur intravitrealen Therapie des Makulaödems bei Uveitis (Stand: 02. 07. 2014)

Erstpublikation

Ophthalmologe 2014; 111: 740–748

DOI 10.1007/s00347-014-3130-0

Online publiziert: 15.8.2014

© Springer-Verlag Berlin Heidelberg 2014

• Literatur

• 1 Acharya NR, Hong KC, Lee SM. Ranibizumab for refractory uveitis-related macular edema. Am J Ophthalmol 2009; 148: 303-309
• 2 Adan A, Pelegrin L, Rey A et al. Dexamethasone intravitreal implant for treatment of uveitic persistent cystoid macular edema in vitrectomized patients. Retina 2013; 33: 1435-1440
• 3 Alpsoy E, Durusoy C, Yilmaz E et al. Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 2002; 138: 467-471
• 4 Androudi S, Tsironi E, Kalogeropoulos C et al. Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology 2010; 117: 1612-1616
• 5 Angunawela RI, Heatley CJ, Williamson TH et al. Intravitreal triamcinalone acetonide for refractory uveitic cystoid macular oedema: longterm management and outcome. Acta Ophthalmol Scand 2005; 83: 595-599
• 6 Antonetti DA, Barber AJ, Hollinger LA et al. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem 1999; 274: 23463-23467
• 7 Arcinue CA, Ceron OM, Foster CS. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis. J Ocul Pharmacol Ther 2013; 29: 501-507
• 8 Bae JH, Lee CS, Lee SC. Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-tenon triamcinolone acetonide for treatment of uveitic cystoid macular edema. Retina 2011; 31: 111-118
• 9 Bashshur ZF, Maʼluf RN, Allam S et al. Intravitreal triamcinolone for the management of macular edema due to nonischemic central retinal vein occlusion. Arch Ophthalmol 2004; 122: 1137-1140
• 10 Becker M, Davis J. Vitrectomy in the treatment of uveitis. Am J Ophthalmol 2005; 140: 1096-1105
• 11 Breitbach M, Rack D, Dietzel M et al. Dexamethason-Implantation zur Behandlung des therapierefraktären zystoiden Makulaödems bei nichtinfektiöser Uveitis. Ophthalmologe 2012; DOG Abstract
• 12 Callanan DG, Jaffe GJ, Martin DF et al. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol 2008; 126: 1191-1201
• 13 Cervantes-Castaneda RA, Giuliari GP, Gallagher MJ et al. Intravitreal bevacizumab in refractory uveitic macular edema: one-year follow-up. Eur J Ophthalmol 2009; 19: 622-629
• 14 Chu YK, Chung EJ, Kwon OW et al. Objective evaluation of cataract progression associated with a high dose intravitreal triamcinolone injection. Eye (Lond) 2008; 22: 895-899
• 15 Cordero Coma M, Sobrin L, Onal S et al. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology 2007; 114: 1574-1579
• 16 Deuter CM, Kotter I, Gunaydin I et al. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol 2009; 93: 906-913
• 17 Dugel PU, Rao NA, Ozler S et al. Pars plana vitrectomy for intraocular inflammation-related cystoid macular edema unresponsive to corticosteroids. A preliminary study. Ophthalmology 1992; 99: 1535-1541
• 18 Eckardt C, Bacskulin A. Vitrectomy in intermediate uveitis. Dev Ophthalmol 1992; 23: 232-238
• 19 Erb C, Schlote T. Medikamentöse Augentherapie. 5.. Auflage. Stuttgart: Thieme; 2011
• 20 Farvardin M, Afarid M, Mehryar M et al. Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. Retina 2010; 30: 1530-1535
• 21 Ferrante P, Ramsey A, Bunce C et al. Clinical trial to compare efficacy and side effects of injection of posterior sub-Tenon triamcinolone versus orbital floor methyprednisolone in the management of posterior uveitis. Clin Exp Ophthalmol 2004; 32: 563-568
• 22 Feucht M, Sturm V, Weissmann J et al. [Uveitic cystoid macular edema: intravitreal triamcinolone]. Klin Monatsbl Augenheilkd 2007; 224: 62-65
• 23 Gulati N, Forooghian F, Lieberman R et al. Vascular endothelial growth factor inhibition in uveitis: a systematic review. Br J Ophthalmol 2011; 95: 162-165
• 24 Gutfleisch M, Spital G, Mingels A et al. Pars plana vitrectomy with intravitreal triamcinolone: effect on uveitic cystoid macular oedema and treatment limitations. Br J Ophthalmol 2007; 91: 345-348
• 25 Habot-Wilner Z, Sallam A, Pacheco PA et al. Intravitreal triamcinolone acetonide as adjunctive treatment with systemic therapy for uveitis macular edema. Eur J Ophthalmol 2011; 21: 56-61
• 26 Haller JA, Dugel P, Weinberg DV et al. Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina 2009; 29: 46-51
• 27 Hansen LL, Danisevskis P, Arntz HR et al. A randomised prospective study on treatment of central retinal vein occlusion by isovolaemic haemodilution and photocoagulation. Br J Ophthalmol 1985; 69: 108-116
• 28 Hardman JG, Limbird LE. The pharmacological basis of therapeutics. New York: McGraw-Hill; 1996
• 29 Hogewind BF, Zijlstra C, Klevering BJ et al. Intravitreal triamcinolone for the treatment of refractory macular edema in idiopathic intermediate or posterior uveitis. Eur J Ophthalmol 2008; 18: 429-434
• 30 Ip MS, Scott IU, VanVeldhuisen PC et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009; 127: 1101-1114
• 31 Jaissle GB, Szurman P, Volker M et al. Epiretinal deposit of triamcinolone acetonide at the posterior pole after intravitreal injection. Ophthalmic Surg Lasers Imaging 2007; 38: 238-241
• 32 Kempen JH, Altaweel MM, Holbrook JT et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology 2011; 118: 1916-1926
• 33 Kiryu J, Kita M, Tanabe T et al. Pars plana vitrectomy for cystoid macular edema secondary to sarcoid uveitis. Ophthalmology 2001; 108: 1140-1144
• 34 Kiss S, Wessel MW. Multiple treatments of the sustained release dexamethasone implant for the treatment of posterior non-infectious uveitis. Invest Ophthalmol Vis Sci 2012; ARVO Abstract 1185
• 35 Kok H, Lau C, Maycock N et al. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 2005; 112: 1916
• 36 Kotter I, Gunaydin I, Zierhut M et al. The use of interferon alpha in Behcet disease: review of the literature. Semin Arthritis Rheum 2004; 33: 320-335
• 37 Krause L, Altenburg A, Pleyer U et al. Longterm visual prognosis of patients with ocular Adamantiades-Behcetʼs disease treated with interferon-alpha-2a. J Rheumatol 2008; 35: 896-903
• 38 Kube T, Sutter M, Trittler R et al. Carboxymethylcellulose as a new carrier substance for intravitreal injection of reproducible amounts of triamcinolone. Graefes Arch Clin Exp Ophthalmol 2006; 244: 1385-1390
• 39 Kuppermann BD, Blumenkranz MS, Haller JA et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007; 125: 309-317
• 40 Ladas ID, Karagiannis DA, Rouvas AA et al. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. Retina 2009; 29: 313-318
• 41 Landa G, Amde W, Doshi V et al. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration. Ophthalmologica 2009; 223: 370-375
• 42 Lasave AF, Zeballos DG, El-Haig WM et al. Short-term results of a single intravitreal bevacizumab (avastin) injection versus a single intravitreal triamcinolone acetonide (kenacort) injection for the management of refractory noninfectious uveitic cystoid macular edema. Ocul Immunol Inflamm 2009; 17: 423-430
• 43 Lashay AR, Rahimi A, Chams H et al. Evaluation of the effect of acetazolamide on cystoid macular oedema in patients with Behcetʼs disease. Eye (Lond) 2003; 17: 762-766
• 44 Leder HA, Jabs DA, Galor A et al. Periocular triamcinolone acetonide injections for cystoid macular edema complicating noninfectious uveitis. Am J Ophthalmol 2011; 152: 441-448
• 45 Levin MH, Pistilli M, Daniel E et al. Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema. Ophthalmology 2014; 121: 588-595
• 46 Lott MN, Schiffman JC, Davis JL. Bevacizumab in inflammatory eye disease. Am J Ophthalmol 2009; 148: 711-717
• 47 Lowder C, Belfort jr. R, Lightman S et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011; 129: 545-553
• 48 Luke M, Januschowski K, Beutel J et al. The effects of triamcinolone crystals on retinal function in a model of isolated perfused vertebrate retina. Exp Eye Res 2008; 87: 22-29
• 49 Maca SM, Abela-Formanek C, Kiss CG et al. Intravitreal triamcinolone for persistent cystoid macular oedema in eyes with quiescent uveitis. Clin Experiment Ophthalmol 2009; 37: 389-396
• 50 Mackensen F, Heinz C, Becker MD et al. Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study. Retina 2008; 28: 41-45
• 51 Mackensen F, Jakob E, Springer C et al. Interferon versus methotrexate in intermediate uveitis with macular edema: results of a randomized controlled clinical trial. Am J Ophthalmol 2013; 156: 478-486
• 52 Miserocchi E, Modorati G, Pastore MR et al. Dexamethasone intravitreal implant: an effective adjunctive treatment for recalcitrant noninfectious uveitis. Ophthalmologica 2012; 228: 229-233
• 53 Moldow B, Sander B, Larsen M et al. The effect of acetazolamide on passive and active transport of fluorescein across the blood-retina barrier in retinitis pigmentosa complicated by macular oedema. Graefes Arch Clin Exp Ophthalmol 1998; 236: 881-889
• 54 Morrison VL, Kozak I, LaBree LD et al. Intravitreal triamcinolone acetonide for the treatment of immune recovery uveitis macular edema. Ophthalmology 2007; 114: 334-339
• 55 Myong JS, Aaker GD, Kiss S. Treatment of noninfectious posterior uveitis with dexamethason intravitreal implant. Clin Ophthalmol 2010; 6: 1423-1426
• 56 Nehme A, Edelman J. Dexamethasone inhibits high glucose-, TNF-alpha-, and IL-1beta-induced secretion of inflammatory and angiogenic mediators from retinal microvascular pericytes. Invest Ophthalmol Vis Sci 2008; 49: 2030-2038
• 57 Pavesio C, Zierhut M, Bairi K et al. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology 2010; 117: 567-575
• 58 Pleyer U, Klamann M, Winterhalter S et al. Ozurdex: a new therapeutic option in uveitis – clinical outcome from two German centers. Invest Ophthalmol Vis Sci 2012; ARVO Abstract 2249
• 59 Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany on the current therapeutic possibilities for neovascular age-related macular degeneration. Klin Monatsbl Augenheilkd 2007; 224: 559-566
• 60 Radetzky S, Walter P, Fauser S et al. Visual outcome of patients with macular edema after pars plana vitrectomy and indocyanine green-assisted peeling of the internal limiting membrane. Graefes Arch Clin Exp Ophthalmol 2004; 242: 273-278
• 61 Radwan AE, Arcinue CA, Yang P et al. Bromfenac alone or with single intravitreal injection of bevacizumab or triamcinolone acetonide for treatment of uveitic macular edema. Graefes Arch Clin Exp Ophthalmol 2013; 251: 1801-1806
• 62 Roesel M, Gutfleisch M, Heinz C et al. [Effect of intravitreal and orbital floor triamcinolone acetonide injection on intraocular inflammation in patients with active non-infectious uveitis]. Klin Monatsbl Augenheilkd 2009; 226: 110-114
• 63 Roesel M, Gutfleisch M, Heinz C et al. Intravitreal and orbital floor triamcinolone acetonide injections in noninfectious uveitis: a comparative study. Ophthalmic Res 2009; 42: 81-86
• 64 Sallam A, Taylor SRJ, Habot-Wilner Z et al. Repeat intravitreal triamcinolone acetonide injections in uveitic macular edema. Acta Ophthalmol 2012; 90: e323-e325
• 65 Schilling H, Heiligenhaus A, Laube T et al. Long-term effect of acetazolamide treatment of patients with uveitic chronic cystoid macular edema is limited by persisting inflammation. Retina 2005; 25: 182-188
• 66 Scott IU, Ip MS, VanVeldhuisen PC et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009; 127: 1115-1128
• 67 Shen L, You Y, Sun S et al. Intraocular and systemic pharmacokinetics of triamcinolone acetonide after a single 40-mg posterior subtenon application. Ophthalmology 2010; 117: 2365-2371
• 68 Soheilian M, Rabbanikhah Z, Ramezani A et al. Bevacizumab vs. triamcinolone. Ophthalmology 2010; 117: 855
• 69 Soheilian M, Karimi S, Ramezani A et al. Pilot study of intravitreal injection of diclofenac for treatment of macular edema of various etiologies. Retina 2010; 30: 509-515
• 70 Soheilian M, Eskandari A, Ramezani A et al. A pilot study of intravitreal diclofenac versus intravitreal triamcinolone for uveitic cystoid macular edema. Ocul Immunol Inflamm 2013; 21: 124-129
• 71 Taylor SRJ, Banker A, Schlaen A et al. Intraocular methotrexate can induce extended remission in some patients in noninfectious uveitis. Retina 2013; 33: 2149-2154
• 72 Thomas ER, Wang J, Ege E et al. Intravitreal triamcinolone acetonide concentration after subtenon injection. Am J Ophthalmol 2006; 142: 860-861
• 73 Tranos PG, Tsaousis KT, Vakalis AN et al. Long-term follow-up of inflammatory cystoid macular edema. Retina 2012; 32: 1624-1628
• 74 Venkatesh P, Abhas Z, Garg S et al. Prospective optical coherence tomographic evaluation of the efficacy of oral and posterior subtenon corticosteroids in patients with intermediate uveitis. Graefes Arch Clin Exp Ophthalmol 2007; 245: 59-67
• 75 Verbraeken H. Therapeutic pars plana vitrectomy for chronic uveitis: a retrospective study of the long-term results. Graefes Arch Clin Exp Ophthalmol 1996; 234: 288-293
• 76 Weiss K, Steinbrugger I, Weger M et al. Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab. Eye 2009; 23: 1812-1818
• 77 Whitcup SM, Csaky KG, Podgor MJ et al. A randomized, masked, cross-over trial of acetazolamide for cystoid macular edema in patients with uveitis. Ophthalmology 1996; 103: 1054-1062 (discussion 62–63)
• 78 Wiechens B, Nolle B, Reichelt JA. Pars-plana vitrectomy in cystoid macular edema associated with intermediate uveitis. Graefes Arch Clin Exp Ophthalmol 2001; 239: 474-481
• 79 Williams GA, Haller JA, Kuppermann BD et al. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol 2009; 147: 1048-1054
• 80 Wilson CA, Berkowitz BA, Sato Y et al. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol 1992; 110: 1155-1159